Based on the 10X Genomics Inc stock forecast from 10 analysts, the average analyst target price for 10X Genomics Inc is USD 20.19 over the next 12 months. 10X Genomics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of 10X Genomics Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, 10X Genomics Inc’s stock price was USD 10.90. 10X Genomics Inc’s stock price has changed by -11.49% over the past week, -33.17% over the past month and -76.08% over the last year.
No recent analyst target price found for 10X Genomics Inc
No recent average analyst rating found for 10X Genomics Inc
Company Overview 10X Genomics Inc
N/A
N/A
N/A
N/A
USD
USA
Adjusted Closing Price for 10X Genomics Inc (TXG)
Loading...
Unadjusted Closing Price for 10X Genomics Inc (TXG)
Frequently Asked Questions About 10X Genomics Inc (TXG) Stock
Based on ratings from 10 analysts 10X Genomics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on TXG's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for TXG is USD 20.19 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on TXG's stock to indicate if its overvalued.
The last closing price of TXG's stock was USD 10.90.
Unfortunately we do not currently have any market capitalization data for TXG's stock.
Based on targets from 10 analysts, the average taret price for TXG is projected at USD 20.19 over the next 12 months.
This means that TXG's stock price may go up by +85.21% over the next 12 months.
We can't find any ETFs which contains 10X Genomics Inc's stock.
Sorry, we do not have any data on the number of employees for 10X Genomics Inc.
Sorry we do not have any infomation available on 10X Genomics Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Frequently Asked Questions About 10X Genomics Inc (TXG) Stock
Based on ratings from 10 analysts 10X Genomics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on TXG's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for TXG is USD 20.19 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on TXG's stock to indicate if its overvalued.
The last closing price of TXG's stock was USD 10.90.
Unfortunately we do not currently have any market capitalization data for TXG's stock.
Based on targets from 10 analysts, the average taret price for TXG is projected at USD 20.19 over the next 12 months.
This means that TXG's stock price may go up by +85.21% over the next 12 months.
We can't find any ETFs which contains 10X Genomics Inc's stock.
Sorry, we do not have any data on the number of employees for 10X Genomics Inc.
Sorry we do not have any infomation available on 10X Genomics Inc's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TXG !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
